GlassScriptPhysician profile
Chelle P Wilhelm
NPI 1154529709
$60,580.46
in general payments reported to CMS, 2019-2025
28 companies · $26K in 2025
The $26K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $408 · 2021: $1,213 · 2022: $9,265 · 2023: $9,083 · 2024: $13K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $4,768 · Travel and Lodging: $3,163 · Education: $75.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,925.00 |
| Food and Beverage | $4,767.60 |
| Travel and Lodging | $3,163.48 |
| Education | $75.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $53,931.22 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,703.20 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $917.45 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Regeneron Healthcare Solutions, INC. | $810.26 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $674.86 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $638.72 | 2019-2025 | |
| Octapharma USA, INC. | $294.87 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human), Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $286.88 | 2020-2024 | Hyqvia, Eohilia |
| Pharming Healthcare, INC. | $184.44 | 2019-2025 | Ruconest |
| Galderma Laboratories, L.P. | $137.71 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $137.67 | 2021-2023 | Orladeyo |
| Optinose US, INC. | $125.15 | 2019-2024 | |
| Genzyme Corporation | $104.54 | 2022 | |
| Amgen INC. | $86.53 | 2021-2025 | Tezspire |
| Kaleo, INC. | $68.88 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.51 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.35 | 2019-2022 | |
| Pfizer INC. | $58.91 | 2019-2022 | |
| Leo Pharma INC. | $54.39 | 2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $52.88 | 2020-2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $41.79 | 2021 | |
| Merck Sharp & Dohme LLC | $37.71 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $26.31 | 2025 | Neffy |
| Arcutis Biotherapeutics, INC. | $23.86 | 2025 | Zoryve |
| Mylan Specialty L.P. | $17.59 | 2020 | |
| Philips North America LLC | $14.91 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.36 | 2024 | Voquezna |
| Incyte Corporation | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelle Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.